Incannex announces formation of clinical advisory board for PSX-001 program

Incannex (IXHL) Healthcare announces the formation of a Clinical Advisory Board, CAB, to support the continued advancement of its PSX-001 development program in generalized anxiety disorder. The newly established CAB has been formed to provide independent clinical and scientific guidance as the Company progresses PSX-001 into its next phase of clinical and regulatory development. The CAB will advise Incannex on clinical trial design, endpoint selection, regulatory engagement, and broader strategic approach for PSX-001 as the program advances.